Background: Inborn errors in Toll-like receptor 3 (TLR3)-IFN type I and III pathways have been implicated in susceptibility to herpes simplex virus encephalitis (HSE) in children, but most patients studied do not carry mutations in any of the genes presently associated with HSE susceptibility. Moreover, many patients do not display any TLR3-IFN-related fibroblastic phenotype. Objective: To study other signaling pathways downstream of TLR3 and/or other independent pathways that may contribute to HSE susceptibility. Methods: We used the stable isotope labeling of amino acids in cell culture proteomics methodology to measure changes in the human immortalized fibroblast proteome after TLR3 activation. Results: Cells from healthy controls were compared with cells from a patient with a known genetic etiology of HSE (UNC-93B 2/2 ) and also to cells from an HSE patient with an unknown gene defect. Consistent with known variation in susceptibility of individuals to viral infections, substantial variation in the
Herpes simplex virus encephalitis (HSE) is a devastating infection of the central nervous system (CNS).
1 It is the most common form of sporadic viral encephalitis in Western countries, where it is estimated to occur in approximately 1 in 250,000 individuals per year. It peaks in childhood between the ages of 3 months and 6 years during primary infection with herpes simplex virus 1 (HSV-1), which reaches the CNS via a neurotropic route involving the trigeminal and olfactory nerves. 2, 3 Treatment with acyclovir decreases the mortality rate in affected children, but significant neurologic impairment is observed in most survivors, young children in particular. HSV-1 is widespread and typically innocuous in human populations. Childhood HSE has not been associable with known immunodeficiencies, and its pathogenesis remained elusive until we identified the first 3 genetic etiologies of this condition. 4, 5 Autosomal-recessive UNC-93B deficiency abolishes Toll-like receptor 3 (TLR3), TLR7, TLR8, and TLR9 signaling, 6 whereas autosomal-dominant TLR3 deficiency specifically affects TLR3 signaling. 7 Recently, an autosomaldominant deficiency in TNF receptor-associated factor 3 (TRAF3), an adaptor molecule implicated in the TLR3 pathway, Toll/IL1R domain-containing adaptor inducing IFN-b (TRIF) and TANK-binding kinase (TBK1)-deficient patients has been described. [8] [9] [10] These studies suggested that childhood HSE may result from impaired IFN-a/b and IFN-l production in response to the stimulation of TLR3 by double-stranded RNA intermediates of HSV-1 in the CNS. However, only a small fraction of children with HSE carry mutations in UNC93B1, TLR3, TRAF3, TRIF, or TBK1. The study of proteins implicated in the TLR3-IFN pathway for patients with HSE enrolled in our laboratory (226 patients) has revealed that only a small proportion of patients bear a genetic defect in these proteins. A larger proportion of patients display an impaired production of IFN type I and III on TLR3 stimulation of their fibroblasts. Other patients do not show the fibroblastic phenotype associated with impaired IFN production; in these patients, the gene defect may affect other pathway(s) that are normally activated in fibroblasts after TLR3 stimulation. In the present study, as an approach to define new candidate genes for HSE, we have used proteomics methods to characterize TLR3-dependent pathways in fibroblasts that might be correlated with HSV-1 infection in the CNS.
METHODS

Subjects and patient P case report
The experimental protocol was approved by the Ethical Committee of Necker-Enfants Malades Hospital (Paris, France), and written informed consent was obtained for this study. P is a French boy of nonconsanguineous descent with no family history of encephalitis. At the age of 8 years, he suffered fever, convulsions, and hemiparesis and he was diagnosed with HSE.
Cell purification
Primary human fibroblasts were obtained from biopsies of an UNC-93B-deficient patient, 6 3 healthy controls, and 1 HSE patient with unknown gene defect. They were then transformed with an SV-40 vector, as previously described, 11 to create immortalized fibroblast cell lines: SV40 fibroblasts.
Stable isotope labeling with amino acids in cell culture labeling of human SV40 fibroblasts
Cells were grown for 6 rounds of cell division in Dulbecco modified Eagle medium containing 13C6, 15N4 L-arginine, and 13C6 L-lysine (Invitrogen, Carlsbad, Calif) (heavy medium [H]) supplemented with 10% dialyzed FCS (Invitrogen) to ensure that all the cellular proteins were labeled to saturation. The stable isotope labeling of amino acids in cell culture (SILAC) technique relies on the intrinsic metabolic machinery of the cell to incorporate ''heavy'' amino acids into all newly synthesized proteins. Immortalized fibroblast cell lines were used to achieve the full SILAC incorporation without detrimentally affecting the characteristics of the cell line. Our previous work has demonstrated that SV40-immortalized fibroblasts can successfully be used to study TLR3 signaling. [7] [8] [9] Labeled cells were activated in 24-well plates, at a density of 10 5 cells/well, with 25 mg/mL of polyinosinepolycytidylic acid (poly[I:C]), a TLR3 agonist (InvivoGen, San Diego, Calif), for 24 hours. Unlabeled cells were grown in parallel in medium containing normal amino acids (light medium [L]) and were not stimulated. The SILAC labels were shown to be fully incorporated before the experiment was conducted (data not shown).
Protein separation and in-gel enzymatic digestion
Equal amounts of protein from unlabeled ''light'' (nonstimulated) and labeled ''heavy'' (stimulated) cells were mixed and subsequently separated by using SDS-PAGE (BioRad Laboratories, Hercules, Calif). Proteins were visualized by silver staining (Sigma, St Louis, Mo), and the gel lane was divided into approximately 34 equally sized pieces that were excised from the gel and destained (30 mmol/L K 3 Fe(CN) 6 ; 100 mmol/L Na 2 S 2 O 3 ) prior to further processing. Gel processing was conducted with a Progest Investigator Instrument (DigiLab, Genomics Solutions, Cambridgeshire, United Kingdom) for reduction and alkylation according to established protocols. 12 Briefly, the gel pieces were washed with 3 cycles of 25 mmol/L NH 4 HCO 3 (pH 8.0) and acetonitrile. Finally, gel plugs were rehydrated in 20 mg/mL of sequencing grade modified trypsin (Promega, Hampshire, United Kingdom) and incubated overnight at 378C. Tryptic peptides were eluted, vacuum-dried, and resuspended in 0.1% formic acid.
XCalibur raw files were processed by using Quant.exe and Identify.exe of the MaxQuant suite (version 1.0.13.13), in combination with the Mascot search engine (version 2.2; Matrix Science, London, United Kingdom), and searched against a concatenated International Protein Index human protein database (version 3.54; containing 75,710 entries, including 262 commonly observed contaminants such as porcine trypsin and some human keratins). All proteins were filtered according to a false discovery rate of 1% applied at both peptide and protein levels. Proteins were automatically quantified in the MaxQuant software. In the final results files, all protein groups with a normalized ratio significance B score of .05 or less and a normalized ratio of more than 1.5 were accepted for downstream analysis. Experiments were done in duplicate, and all proteins discussed in the text were significant in both replicates for each sample. For details of mass spectrometry (MS) analysis, protein inference and quantification, analysis of sample correlations, and global functional analysis of protein networks, see Additional methods in this article's Online Repository available at www.jacionline.org.
Transient transfections
SV40 fibroblasts were transfected with 2 mg of pBI-EGFP-MnSOD (superoxide dismutase 2 [SOD2]) or pTRE-Tight-BI-AcGFP1 (Clontech, Palo Alto, Calif) as mock vector, in the presence of the FuGENE HD Transfection Reagent (Roche Applied Science, Indianapolis, Ind), according to manufacturer's instructions. Twenty-four hours posttransfection, SV40 fibroblasts were activated by incubation with 25 mg/mL of poly(I:C) (InvivoGen) for 24 hours. pTRE-Tight-BI-AcGFP1 was used as mock vector (pBI-EGFP has been replaced by AcGFP; it has 94% identical amino acid sequence and same biophysical properties).
Western blot
Total cell extracts were prepared from SV40 fibroblasts, both transfected and not transfected. Equal amounts of protein from each sample were separated by using SDS-PAGE and blotted onto iBlot Gel Transfer Stacks (Invitrogen). Membranes were probed with anti-intercellular adhesion molecule-1 (ICAM-1) rabbit monoclonal (Lifespan Biosciences, Seattle, Wash), anti-SOD2 and ITGA2 monoclonals and anti-ITGA5 and peptidylpropyl cis-trans isomerise mitochondrial (PPIF) polyclonals (Abcam, Cambridge, Mass), anti-ANXA5/7 monoclonals (SantaCruz Biotechnology, Inc, Santa Cruz, Calif), followed by a secondary antimouse or antirabbit IgG (GE Healthcare, Buckinghamshire, United Kingdom). Membranes were stripped and reprobed with anti-glyceraldehyde-3-phosphate dehydrogenase (SantaCruz) to control for protein loading. Antibody binding was detected by using enhanced chemiluminescence (Amersham-Pharmacia-Biotech, Buckinghamshire, United Kingdom).
Apoptosis analysis
Levels of SV40-fibroblast apoptosis after poly(I:C) stimulation were assessed by measures of caspase-3 and caspase-7 activity. Cells were plated, in triplicate, in Microtest 96-well Assay Plate, Optilux Black/Clear Bottom (Falcon; Becton Dickinson, Franklin Lakes, NJ) (1 3 10 4 cells/well), in Dulbecco modified Eagle medium supplemented with 2% FCS; some cells were transfected with 150 ng/well of pBI-EGFP-MnSOD (SOD2) or pTRE-Tight-BI-AcGFP1 as mock vector. Twenty-four hours later, cells were treated with poly(I:C) (25 mg/mL) and incubated for 24 hours. Caspase-3 and caspase-7 activity was measured 48 hours posttransfection by using Caspase-Glo 3/7 Assay (Promega) as per manufacturer's instructions.
IFN type I and III determination
SV40-fibroblast cell lines were activated in 24-well plates at a density of 10 5 cells/well and stimulated with poly(I:C) at a concentration of 25 mg/mL for 24 hours. Cells were grown at 378C under an atmosphere containing 5% CO 2 . Cell supernatants were recovered, and an ELISA was performed for IFN-b (TFB; Fujirebio, Inc, Tokyo, Japan) according to manufacturer's instructions. The ELISA for IFN-l was performed as previously described. 7 
RESULTS
Identification of proteins upregulated in human SV40 fibroblasts following TLR3 activation
Response to TLR3 activation was defined by altered levels of protein abundance in human SV40 fibroblasts when stimulated with poly(I:C) (used as TLR3 agonist [6] [7] [8] [9] ) and was measured by SILAC/MS [13] [14] [15] monitoring of heavy/light isotope labeling ratios for peptides from proteins of stimulated/unstimulated cells (Fig 1, A) .
Three healthy samples (C1, C2, and C3) are positive controls that provide a measure of variability between individuals (Fig 1, B) . Negative control, C2NS, is a healthy sample with strong TLR3 response, but for which neither cell population (light/heavy) was stimulated (Fig 1, B) . The UNC-93B deficiency blocks TLR3, TLR7, TLR8, and TLR9 pathways, and so cells from the UNC-93B 2/2 patient (sample UNC-93B 2/2 ) should not respond to TLR3 agonists. 6 We used SV40 fibroblasts from a homozygous UNC-93B 2/2 patient rather than a patient with heterozygous TLR3 mutation because of the complete deficiency of TLR3 pathways observed in UNC-93B 2/2 cells. 6 Finally, we included cells from an HSE patient with unknown gene defect (P) (Fig 1, B) , which produce detectable amounts of IFN type I after TLR3 stimulation (Fig 2) .
All 6 biological samples were subjected to duplicate MS analysis, 16, 17 and protein lists were obtained by combining both data sets prior to analysis of differential protein abundance (see Tables E1-E6 in We have previously observed variability in response of healthy control fibroblasts on TLR3 stimulation, particularly in terms of cytokine and interferon production (Fig 2) . To take this into account, we included sample C3, from a healthy donor with known weaker response to TLR3 stimulation compared with C1 and C2 (Fig 2) . In line with expectation, this control showed a reduced number of upregulated proteins (19 with SILAC H/L ratios between 1.50-fold and 2.15-fold; Fig 1, C) . Comparison of upregulated proteins between the control samples revealed variation in those proteins most strongly upregulated. This variability might arise from (a) the conservative condition that protein SILAC ratios were calculated from at least 3 separate H/L ratio measurements and/or (b) differences in the extent to which different proteins change in abundance in cells taken from different individuals. A qualitative test of cellular variability among healthy controls 
Detection of functional networks
Given the observed variability in the detection and measurement of specific protein regulation across experiments, we sought common functional networks among the most strongly upregulated proteins to characterize response to TLR3 stimulation and identify disease-related differences by comparison. We used MetaCore version 6.3 (GeneGo, Inc) to investigate pathways and biological functions represented by differentially regulated proteins in all samples (see Additional results and Fig E2) .
The analysis indicated that the most significant GeneGo process networks for C1/C2/C3 are similar and are implicated in immune responses, such as IFN-signaling and antigen presentation pathways (Table I) , known to be implicated following TLR3 stimulation. 18, 19 Similar analysis was performed for the nonstimulated C2NS control sample. The majority of proteins in the nonstimulated control C2NS show SILAC ratios of approximately 1 (Table E4) , which represent ''measurement noise.'' As may be expected, the 8 proteins designated as upregulated (H/ L 5 1.50-3.07-fold) did not associate with canonical pathways or process networks implicated in the immune response, and networks inferred from them were of limited statistical significance and scattered over diverse pathways and processes (Table II) . The UNC-93B 2/2 sample did not associate with the immune-related networks identified above, further suggesting that the TLR3 pathway is completely abolished by this deficiency (Table II) . UNC-93B 2/2 did, however, yield several upregulated proteins (Table  E5) , with SILAC ratios of 1.5 to 3.95-fold, which may represent attempts by these cells to compensate for the genetic defect. Canonical pathways associated with these proteins were largely metabolic (glycolysis, gluconeogenesis, fructose metabolism), however, and process networks inferred were particularly diverse (Table II) .
The same analysis was also performed on the union of proteins upregulated in C1/C2/C3 (152 proteins, excluding 7 proteins in common with C2NS or UNC-93B 2/2 samples), strengthening the association between TLR3 stimulation and IFN-a/b signaling pathways (Table I; The analysis of healthy controls also revealed other statistically significant proteins/pathways/processes ( Table I ) that do not appear in similar analysis of C2NS or UNC-93B 2/2 samples (Table II) , and which have not been associated previously with TLR3 pathways. Such proteins included ICAM-1, integrins ITGA2 and ITGA5, and SOD2 (Table I) . Furthermore, some proteins upregulated by TLR3 stimulation in healthy controls were not placed in pathways/networks by GeneGo but are associated with a role in HSV infection in the CNS by literature evidence. These proteins include several annexins and peptidyl-propyl cis-trans isomerise mitochondrial (PPIF) (Tables E1-E3), the majority of which were not identitied as differentially regulated by analysis of UNC-93B 2/2 (Fig 3, A) . Table E8 in this article's Online Repository available at www.jacionline.org shows MS data for individual peptides assigned to these proteins and confirms the quality of their detection and assignment. The expression of these proteins was confirmed by western blot (see Fig  E5 in this article's Online Repository available at www. jacionline.org), and they are considered further in the discussion.
Finally, although not the primary focus of our analysis, the union of proteins commonly downregulated on TLR3 stimulation in healthy controls C1/C2/C3 was subjected to similar pathway analysis. The results are summarized in Tables E1 to E3 and reflect strongest association with cytoskeleton remodeling and negative regulation of cell cycle, in accordance with the apoptosis induced on TLR3 stimulation and in agreement, for example, with the upregulation of annexins identified above.
Proteomics of TLR3-stimulated fibroblasts reveals potential new treatments for HSE: SOD2 upregulation
SOD2 is highly upregulated in healthy patient samples C1, C2, and C3 after TLR3 stimulation but not in cells from a patient with , UNC-93B-deficient patient.
known genetic deficiency UNC-93B
2/2 and neither in unstimulated healthy control sample C2NS (Fig 3, A) . SOD2 is an antioxidant enzyme strongly upregulated after TLR3 activation in macrophages, protecting these cells from oxidative stress during microbial infection. 20 SOD2 is increased after HSV-1 infection, and SOD2 levels in the CNS are associated with neuronal protection. 21, 22 Other examples of the protective role of SOD2 have been shown in an animal model of complex I deficiency, 23 in which SOD2 gene transfer in vivo enhanced cellular resistance to reactive oxygen species and suppressed degeneration of the Notes. Upper panels: Pathways/networks known to be implicated in TLR3-IFN signaling. Lower panels: New pathways/networks activated. Threshold: 1.5 (SILAC ratio), Significance B P value <.05. Sorting method is statistically significant. Boldface names are proteins with potential biological significance in HSE.
J ALLERGY CLIN IMMUNOL VOLUME 131, NUMBER 4 optic nerve. 23 This suggests SOD2 as a putative target for future treatment of HSE, in particular to reduce the neurologic sequelae that patients suffer after encephalitis.
We used gene transfer to further investigate the role of SOD2 in human-transformed fibroblasts. Western-blot analysis of healthy cells confirmed the upregulation of SOD2 after poly(I:C) stimulation, and very low levels of SOD2 in UNC-93B
2/2 cells suggested that the defect affects SOD2 expression (Fig 4, A) . We detected SOD2 overexpression after transient transfections of pBI-EGFP-MnSOD (SOD2), but not with mock transfected vector (Fig 4, A) . The measurement of apoptosis in SV40 fibroblasts transfected with SOD2 showed that healthy cells overexpressing SOD2 are protected against apoptosis and that this is also the case for stimulation with poly(I:C). Relative apoptosis measured in poly(I:C)-stimulated UNC-93B 2/2 cells against their nonstimulated counterpart was higher than similar measurement for healthy controls, indicating UNC-93B 2/2 patient cells as more susceptible to apoptosis than healthy cells after TLR3 activation. When transfected with SOD2, however, UNC-93B 2/2 patient cells were protected against apoptosis (Fig 4, B) . Together, these results suggest that pharmacologic agents that upregulate SOD2 expression or activity could exert a protective antioxidant response mechanism to reduce the cell death associated with TLR3 stimulation in patients with HSE.
Analysis of a patient with unknown gene defect and without fibroblastic phenotype
Thirty percent of patients with HSE analyzed do not show the fibroblastic phenotype characterized by reduced IFN type I and III production after TLR3 stimulation (data not shown). In these patients, study of the TLR3-stimulated proteome may help delineate the source(s) of the different cellular phenotype. We conducted a SILAC analysis of a patient whose genetic defect is unknown but that produces significant amounts of IFN type I and III after TLR3 stimulation (see Fig E6, A, in this article's Online Repository available at www.jacionline.org). The study identified many upregulated proteins shared with stimulated healthy control . The proteins shared those highlighted during earlier analysis of the stimulated healthy controls, with the exception of ICAM-1, which was not detected poststimulation (Fig 3, A, and Table E6) as confirmed by western-blot analysis (Fig E6, B) . ITGA5 (H/L 5 1.65) and ANX11 (H/L 5 1.29) are upregulated in patient sample P, but at a significance ratio just outside the threshold of significance B (<.05) (Table E6 ). GeneGo analysis also inferred process networks similar to those related to the stimulation of healthy controls, involving immune responses such as IFN signaling and antigen presentation pathways (Table II) . This result concurs with previous studies that show cells from patient P to exhibit IFN type I and III production after TLR3 signaling (Fig E6,  A) . Given the extent of overlap between the analysis of TLR3 stimulation effect in patient P and that in healthy control samples, the nondetectable levels of ICAM-1 on TLR3 stimulation in P, identified via proteomic analysis, provide an avenue in this patient for a candidate approach centred on ICAM-1 and related genes/ proteins. This would be the first such approach in a patient with HSE to involve pathways beyond TLR3-IFN signaling. A, For proteins with potential biological significance in HSE, the SILAC ratio detected for healthy controls (C1-3), healthy control 2 nonstimulated (C2NS), UNC-93B-deficient patient (UNC-93B 2/2 ), and patient with unknown gene defect (P). Significance B P value <.05. B, Illustration of potential biological significance in immunity against HSE for proteins upregulated after TLR3 activation. ds, Double stranded.
DISCUSSION
The quantitative SILAC analysis presented here provides important preliminary evidence to suggest that several proteins, pathways, and processes could play important and novel roles in TLR3 response and HSE immunity.
ICAM-1 upregulation
After TLR3 stimulation, healthy controls C1, C2, and C3 displayed ICAM-1 upregulation, as described previously, 24, 25 but there was no corresponding upregulation in UNC-93B 2/2 , patient P, or nonstimulated C2NS (Fig 3, A, and Fig E6) . ICAM-1 is an intercellular adhesion molecule implicated in HSV-1 infection in the CNS. 26, 27 The present results suggest that lack of ICAM upregulation may be an important factor in susceptibility to HSE, especially for those patients (eg, P) who show substantial IFN production and lack the fibroblastic phenotype.
Upregulation of integrins ITGA2 and ITGA5
We detected ITGA2 and ITGA5 upregulation after TLR3 stimulation in healthy cells but not in C2NS or UNC-93B 2/2 (Fig  3, A) . Cells from patient P showed significant upregulation of ITGA2 (Fig 3, A) and upregulation of ITGA5 (H/L 5 1.65) just beyond the significance threshold used (Table E6) . Some studies have demonstrated that integrins are necessary for HSV-1 entry/ fusion in cells 28 and ITGA2 is upregulated in chronic hepatitis virus infection. 29 The present results identify specific integrins upregulated following TLR3 activation and whose further investigation might offer new insights into HSE susceptibility.
Upregulation of annexins
After TLR3 stimulation in healthy cells, we detected upregulation of several annexins (Fig 3, A) . Microglial cells, after activation in response to harmful stimuli, are able to induce neuronal Luciferase activity represented as percentage; 100% is healthy control nonstimulated. Mean values 6 SD were calculated from 3 independent experiments. Two-sided test was used, and a P value of less than .05 was considered statistically significant. C, Healthy control C3; UNC-93B 2/2 , UNC-93B-deficient patient; 2, nonstimulated; 1, poly(I:C) stimulated.
cell death by ANX1 30 and ANX5 upregulation. 31 It has been shown that TLR3 activation with poly(I:C) and HSV-1 infection induce apoptosis by enhancing ANX5 levels. [32] [33] [34] The present data suggest possible roles for ANX5, ANX6, and ANX7 in the activation and subsequent apoptosis of immune cells in the CNS on viral infection.
PPIF upregulation
PPIF protein was upregulated after TLR3 stimulation in healthy and patient P cells but not in those with the UN-C-93B 2/2 defect (Fig 3, A) . PPIF, also called cyclophilin D, is part of the mitochondrial permeability transition pore in the inner mitochondrial membrane. Activation of this pore is thought to be involved in the induction of apoptotic and necrotic cell death. HSV-1 infection of neurons is known to induce cell death, and PPIF has been previously described as a key protein in neuronal cell death. [35] [36] [37] This is the first report of a relationship between PPIF and TLR3, suggesting a possible role for PPIF in HSE immunity.
Previous studies have shown that the TLR3 pathway is essential for susceptibility to HSE. [6] [7] [8] However, the analysis of many proteins downstream of TLR3 implicated in the TLR3-IFN type I pathway has failed to reveal a genetic defect in most patients analyzed. In 226 patients enrolled in our laboratory, we have detected mutations in UNC93B1, TLR3, or genes downstream of the TLR3 pathway in a very low percentage. Conversely, study of IFN type I and III production after TLR3 activation in SV40 fibroblasts of patients with HSE has shown that only 30%, of a total of 89 patients analyzed, have normal IFN type I and III production (data not shown). This suggests that despite the importance of the TLR3 pathway in HSE immunity, genetic defect(s) responsible for susceptibility to HSV-1 in the CNS could be due to TLR3-independent pathways, or other TLR3, IFN-dependent pathways that are activated after initial TLR3 activation. Overall, the present results suggest a rich diversity of pathways downstream of TLR3 activation that may be relevant for HSE susceptibility and that invite further investigation.
Proteomic analysis of a patient (P) with unknown gene defect but without the fibroblastic phenotype has revealed a lack of ICAM-1, delineating a cellular phenotype that may assist dissection of this genetic etiology. Finally, an important problem in this pathology is postinfection neurologic sequelae, for which the current treatment is aciclovir, an antiviral drug. However, this treatment is largely uneffective. 2 The present study has now revealed SOD2 as a possible therapeutic target for the prevention of the neurologic sequelae suffered by patients with HSE.
Proteomics has reached the stage where its methods are well developed and capable of generating large, robustly identified, high-resolution quantitative data sets that provide a wealth of knowledge at the systems level. Even for a disease such as HSE, of apparent etiological diversity, coupled with the cellular diversity evident among individuals, proteomics has provided an integrated overview of cellular responses that may be crucial for understanding the dynamics of HSE susceptibility.
